Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell disease
AssigneesVirginia Commonwealth University, IllExcor Therapeutics, LLC, King Abdulaziz University, Children's Hospital of Philadelphia (Chop)
InventorsMartin SAFO, Yan ZHANG, Andrew FLEISCHMAN, David LIGHT, Moustafa EL-ARABY, Abdelsattar OMAR, Osheiza ABDULMALIK
Life of this patent
Estimating the term…
Abstract
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
Claims11
A compound having a formula
- wherein
- W, X, Y and Z are the same or different and are independently C or N, with the proviso that at least one of W, X, Y and Z is N;
- and
- R1, R2, R3, and R4 are the same or different and independently F, Cl or H, and pharmaceutically acceptable salts or oral prodrugs thereof.
A method of preventing or treating one or more symptoms or conditions of sickle cell disease (SCD) in a subject in need thereof, comprising
- administering to the subject a therapeutically effective amount of a compound, or a salt or prodrug which is metabolized or otherwise converted in a subject to said compound, having the formula
- wherein
- W, X, Y and Z are the same or different and are independently C or N, with the proviso that at least one of W, X, Y and Z is N;
- and
- R1, R2, R3, and R4 are the same or different and independently F, Cl or H.
Dependencies are inferred from the claim text.